Skip to main content
Premium Trial:

Request an Annual Quote

Plexera, MitoSciences to Develop Mitochondrial Antibody Array for ADME/Tox

NEW YORK (GenomeWeb News) – Lumera subsidiary Plexera Bioscience said today that it has struck an agreement with MitoSciences to develop an antibody array based on Plexera’s ProteomicProcessor biosensor technology and MitoSciences’ antibodies.
Plexera said the development agreement is “in conjunction with” a previous agreement under which parent firm Lumera partnered with the Medical University of South Carolina to develop a protein-expression profiling assay.
The array will measure changes in mitochondrial proteins, which “are known to be markers for certain pathologies and many adverse drug effects,” said Craig Beeson, associate professor of pharmaceutical sciences at MUSC and the principal investigator on the project.
Plexera COO Tim Londergan said the co-developed array “has the potential to become a mainstream assay” in pharmacokinetics, pharmacology, and toxicology “as pharmaceutical companies desperately need to find new ways to screen and eliminate problematic compounds sooner in the process."
Plexera said the US ADME/Tox market is growing at a compound annual growth rate of 17.2 percent and is expected to reach $2.8 billion in 2009.
Financial terms of the development agreement were not released.
The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.